Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

Bhaskar Venkata Kameswara Subrahmanya Lakkakula; Batoul Farran; Saikrishna Lakkakula; Sujatha Peela; Nagendra Sastry Yarla; Pallaval Veera Bramhachari; Mohammad Amjad Kamal; Madhu Sudhana Saddala; Ganji Purnachandra Nagaraju

doi:10.1016/j.semcancer.2018.09.011

Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

Bhaskar Venkata Kameswara Subrahmanya Lakkakula, Batoul Farran, Saikrishna Lakkakula, Sujatha Peela, Nagendra Sastry Yarla, Pallaval Veera Bramhachari, Mohammad Amjad Kamal, Madhu Sudhana Saddala, Ganji Purnachandra Nagaraju

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.

Original language	English (US)
Pages (from-to)	149-167
Number of pages	19
Journal	Seminars in Cancer Biology
Volume	56
DOIs	https://doi.org/10.1016/j.semcancer.2018.09.011
State	Published - Jun 2019
Externally published	Yes

Keywords

Clinical trials
Pancreatic carcinoma
Resistance
Targeted therapies
Tyrosine kinase inhibitors

ASJC Scopus subject areas

Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.semcancer.2018.09.011

Cite this

@article{8d456dce19024257800fa19820323430,

title = "Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles",

abstract = "Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.",

keywords = "Clinical trials, Pancreatic carcinoma, Resistance, Targeted therapies, Tyrosine kinase inhibitors",

author = "Lakkakula, {Bhaskar Venkata Kameswara Subrahmanya} and Batoul Farran and Saikrishna Lakkakula and Sujatha Peela and Yarla, {Nagendra Sastry} and Bramhachari, {Pallaval Veera} and Kamal, {Mohammad Amjad} and Saddala, {Madhu Sudhana} and Nagaraju, {Ganji Purnachandra}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2019",

month = jun,

doi = "10.1016/j.semcancer.2018.09.011",

language = "English (US)",

volume = "56",

pages = "149--167",

journal = "Seminars in Cancer Biology",

issn = "1044-579X",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

AU - Lakkakula, Bhaskar Venkata Kameswara Subrahmanya

AU - Farran, Batoul

AU - Lakkakula, Saikrishna

AU - Peela, Sujatha

AU - Yarla, Nagendra Sastry

AU - Bramhachari, Pallaval Veera

AU - Kamal, Mohammad Amjad

AU - Saddala, Madhu Sudhana

AU - Nagaraju, Ganji Purnachandra

PY - 2019/6

Y1 - 2019/6

N2 - Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.

AB - Pancreatic cancer (PC) is an aggressive carcinoma and the fourth cause of cancer deaths in Western countries. Although surgery is the most effective therapeutic option for PC, the management of unresectable, locally advanced disease is highly challenging. Our improved understanding of pancreatic tumor biology and associated pathways has led to the development of various treatment modalities that can control the metastatic spread of PC. This review intends to present trials of small molecule tyrosine kinase inhibitors (TKIs) in PC management and the troubles encountered due to inevitable acquired resistance to TKIs.

KW - Clinical trials

KW - Pancreatic carcinoma

KW - Resistance

KW - Targeted therapies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85054426727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054426727&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2018.09.011

DO - 10.1016/j.semcancer.2018.09.011

M3 - Review article

C2 - 30314681

AN - SCOPUS:85054426727

SN - 1044-579X

VL - 56

SP - 149

EP - 167

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

ER -

Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this